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Mycobacterium abscessus (Mab) infections are a growing menace to the health
of many patients, especially those suffering from structural lung disease and cystic ﬁbrosis.
With multidrug resistance a common feature and a growing understanding of peptidoglycan synthesis in Mab, it is advantageous to identify potent b -lactam and b -lactamase inhibitor combinations that can effectively disrupt cell wall synthesis. To improve existing
therapeutic regimens to address serious Mab infections, we evaluated the ability of durlobactam (DUR), a novel diazobicyclooctane b -lactamase inhibitor to restore in vitro susceptibilities in combination with b -lactams and provide a biochemical rationale for the activity
of this compound. In cell-based assays, susceptibility of Mab subsp. abscessus isolates to
amoxicillin (AMOX), imipenem (IMI), and cefuroxime (CXM) was signiﬁcantly enhanced with
the addition of DUR. The triple drug combinations of CXM-DUR-AMOX and IMI-DUR-AMOX
were most potent, with MIC ranges of #0.06 to 1 m g/mL and an MIC50/MIC90 of #0.06/
0.25 m g/mL, respectively. We propose a model by which this enhancement may occur,
DUR potently inhibited the b -lactamase BlaMab with a relative Michaelis constant (Ki app) of
4  1023 6 0.8  1023 m M and acylation rate (k2/K) of 1  107 M21 s21. Timed mass
spectrometry captured stable formation of carbamoyl-enzyme complexes between DUR
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and LdtMab2-4 and Mab D,D-carboxypeptidase, potentially contributing to the intrinsic activity
of DUR. Molecular modeling showed unique and favorable interactions of DUR as a BlaMab
inhibitor. Similarly, modeling showed how DUR might form stable Michaelis-Menten complexes with LdtMab2-4 and Mab D,D-carboxypeptidase. The ability of DUR combined with
amoxicillin or cefuroxime and imipenem to inactivate multiple targets such as D,D-carboxypeptidase and LdtMab2,4 supports new therapeutic approaches using b -lactams in eradicating Mab.
IMPORTANCE Durlobactam (DUR) is a potent inhibitor of BlaMab and provides protection
of amoxicillin and imipenem against hydrolysis. DUR has intrinsic activity and forms stable
acyl-enzyme complexes with LdtMab2 and LdtMab4. The ability of DUR to protect amoxicillin
and imipenem against BlaMab and its intrinsic activity along with the dual b -lactam target
redundancy can explain the rationale behind the potent activity of this combination.
KEYWORDS antibiotic resistance, bacteria, inhibitor, antibiotics, durlobactam,

b -lactams, Mycobacterium abscessus, b -lactamase inhibitor, diazabicyclooctane,
Mycobacterium
ycobacterium abscessus (Mab) is a multidrug-resistant (MDR) nontuberculous
mycobacterium (NTM) that causes invasive pulmonary and disseminated infections, particularly in patients with structural lung disease, cystic ﬁbrosis, or compromised immunity (1). Recently updated guidelines by four international societies, the
American Thoracic Society (ATS), European Respiratory Society (ERS), European Society
of Clinical Microbiology and Infectious Diseases (ESCMID), and Infectious Diseases
Society of America (IDSA) published in July 2020 recommend a multidrug regimen that
contains at least three active antimicrobials (2). However, treatment outcomes remain
poor compared to other mycobacterial diseases (3), and the optimal combination and
duration of therapy remain unknown. Furthermore, the presence of acquired or inducible macrolide resistance [23S rRNA mutations or erm(41) induction, respectively] is
associated with a signiﬁcant rate of treatment failure (2, 4, 5). In focal pulmonary infections, surgical resection of bronchiectatic lung lobes is often recommended, reminiscent of the dramatic approach to drug-susceptible pulmonary tuberculosis in the era
before chemotherapy. Novel therapeutic strategies with sustainable efﬁcacy for the
treatment of Mab are needed.
b -Lactams and b -lactamase inhibitors (BLIs) are agents that may provide promise
for Mab infections. Within the current guidelines, imipenem (IMI) and cefoxitin (FOX)
are the only two b -lactam antibiotics recommended for inclusion in a multidrug regimen (1). Unfortunately, IMI- and FOX-resistant isolates are reported (5). Nevertheless,
insights into the intrinsic mechanisms of b -lactam resistance provide opportunities to
expand the use of this drug class. One such important mechanism of resistance is
BlaMab, a class A b -lactamase encoded on a Mab gene. BlaMab demonstrates catalytic activity against penicillins, some cephalosporins, and to a lesser extent, carbapenems;
BlaMab hydrolyzes FOX and IMI, albeit at a comparatively lower rate (low k2/K) than
other b -lactams (6). Unlike BlaC, the b -lactamase of Mycobacterium tuberculosis, BlaMab
is poorly inhibited by clavulanate (6).
Another important source of b -lactam resistance in Mab are the L,D-transpeptidases
(Ldts). The better-studied D,D-transpeptidases (Ddts; also referred to as high-molecularweight penicillin-binding proteins or HMW PBPs) form 4,3-cross-links between adjacent
peptidoglycan stem peptides. In contrast, Ldts form 3,3-cross-links, and in Mab, this
linkage predominates (7). Ldts in Mab are resistant to penicillins but are inhibited by
carbapenems and some cephalosporins (8, 9). Important to the function of Ldts are
the D,D-carboxypeptidases (D,D-c), a group of low-molecular-weight penicillin-binding
proteins (LMW PBPs) that convert pentapeptides of peptidoglycan subunits to tetrapeptides that can subsequently be used by Ldts; these enzymes also appear to be
inhibited by b -lactams (10).
Recently, it was hypothesized that the synergy exhibited by dual b -lactams in
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susceptibility studies may be driven by inhibition of multiple enzymes in the peptidoglycan
synthesis pathway (i.e., “target redundancy”) (8, 9). This “target redundancy” may lead to an
unanticipated synergistic effect using b -lactam combinations. This hypothesis is supported
by the ﬁnding that combinations of certain b -lactams and b -lactamase inhibitors inhibit
more than one critical enzyme in the cell wall synthesis process. In addition to inhibition of
Ldts, select cephalosporins and carbapenems are known to inhibit the traditionally recognized targets of b -lactams (Ddts). Sayed et al. demonstrated that PBPs of Mab (PonA1,
PonA2, and PbpA) are inhibited by ceftriaxone, cefotaxime, and carbapenems at relatively
low concentrations (11). Interest in combinations of b -lactams with and without b -lactamase inhibitors is growing as laboratory ﬁndings demonstrate improvement of in vitro susceptibilities in Mab isolates (9, 12–15). The application of these ﬁndings awaits in vivo
studies.
Diazabicyclooctanes (DBOs) are a recently developed class of b -lactamase inhibitors that
may provide an opportunity to address the challenges of BlaMab and Ldts and expand the
use of b -lactams in the treatment of Mab. Avibactam, nacubactam, and zidebactam restore
susceptibility to b -lactams and inhibit growth of Mab in vitro (16–20). The DBO avibactam is
a potent inhibitor of BlaMab (21). DBOs also participate in the inhibition of peptidoglycan
transpeptidases. Avibactam has been shown to inhibit L,D transpeptidation of M. tuberculosis
(Mtb) and form carbamoyl-enzyme complexes with some Ldts of Mtb and Mab (9, 22). DBO
inhibition of Ldts may be important not only for ensuring broad inhibition of multiple Ldts,
Ddts, and D,D-c but also for exploiting the notion of target redundancy that may underlie
the synergy between some drug combinations.
Durlobactam (DUR, previously designated ETX2514) is a novel DBO with the unique
features of a double bond within the DBO ring between C-3 and C-4 and a methyl
group at C-3 (Fig. 1); these features enhance reactivity and binding to b -lactamases
(23). As such, DUR is a potent inhibitor of class A, C, and D serine b -lactamases. It is currently in clinical development in combination with sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii infections. To date, DUR activity against
BlaMab and LdtMab of Mab has not been investigated. As part of a concerted effort to
improve existing therapeutic regimens to address serious Mab infections, we sought to
evaluate the ability of DUR to restore in vitro susceptibilities in combination with b -lactams and provide a biochemical rationale for activity. We hypothesized that DUR
would act as a “dual function” compound and enhance the activity of b -lactam partners through both protection from BlaMab and inhibition of peptidoglycan transpeptidation. We also propose a model by which this enhancement may occur.
RESULTS
Susceptibility of Mycobacterium abscessus subsp. abscessus isolates to amoxicillin,
imipenem, or cefuroxime is enhanced by the addition of DUR. An initial assessment
of antibacterial activity for amoxicillin (AMOX), IMI, and DUR alone plus each of the
b -lactams in a 1:1 combination with DUR was determined for M. abscessus (Mab)
ATCC 19977 in Middlebrook 7H9 broth supplemented with 10% (vol/vol) oleic
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FIG 1 Structures of the DBOs, avibactam, and DUR (ETX2514).
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TABLE 1 Summary of activity of DUR, AMOX, IMI, or CXM alone or in various combinations against 101 clinical isolates of Maba
MIC (mg/mL)
Antibiotic
DUR
AMOX
IMI
IMI-AMOX
AMOX-DUR
IMI-DUR
IMI-DUR-AMOX
CXM
CXM-AMOX
CXM-DUR
CXM-DUR-AMOX

Test method
Alone
Alone
Alone
Titrate IMI 1 AMOX ﬁxed at 8 m g/mL
Fixed 1:1 ratio
Fixed 1:1 ratio
Titrate IMI-DUR 1:1 1 AMOX ﬁxed at 8 m g/mL
Alone
Titrate CXM 1 AMOX ﬁxed at 8 m g/mL
Fixed 1:1 ratio
Titrate CXM-DUR 1:1 1 AMOX ﬁxed at 8 m g/mL

Range
228
128 to .256
124
0.2528
124
0.524
#0.0622
42128
0.5 to .64
0.524
#0.0621

MIC50
4
.256
4
1
2
2
#0.06
8
4
2
#0.06

MIC90
8
.256
4
2
4
2
0.25
16
8
2
0.25

aDUR,

albumin dextrose catalase and 0.05% (vol/vol) Tween 80. As anticipated, IMI had better activity than AMOX alone with MIC values ranging from 0.5 to 4 m g/mL. Unlike
avibactam and relebactam (9), DUR demonstrates antimicrobial activity with MIC values ranging from 2 to 8 m g/mL. The MIC values for AMOX-DUR combination were
one twofold dilution lower than those for DUR alone, and the MIC values for the IMIDUR combination were generally one twofold dilution lower than those for IMI alone
(Table 1 and Fig. 2).
Further exploration of the antibacterial activity of combinations of b -lactams and
DUR in our entire set of previously characterized isolates of Mab subsp. abscessus
revealed speciﬁc susceptibilities to the combinations of AMOX, IMI, and DUR.
Cefuroxime (CXM) alone and in combination with DUR or AMOX, IMI-DUR, and triple
combinations of IMI-DUR-AMOX and CXM-DUR-AMOX were also tested against our
clinical isolates (Table 1 and Fig. 2).
The intrinsic antibacterial activity of DUR for this larger collection of Mab isolates
was similar to that observed against Escherichia coli and other Enterobacterales spp.
(23), with an MIC50/MIC90 of 4/8 m g/mL. IMI also showed similar activity against Mab as
observed in the previous study (9), with an MIC50/MIC90 of 4/4 m g/mL. Addition of DUR
to IMI in a 1:1 ﬁxed ratio improved the MIC50/MIC90 value by one dilution (to 2/2 m g/
mL). AMOX added at a ﬁxed concentration of 8 m g/mL to IMI had an even greater
effect, lowering the MIC50/MIC90 to 1/2 m g/mL. Addition of DUR to AMOX in a 1:1 ﬁxed
ratio also improved the MIC50/MIC90 (to 2/4 m g/mL). The triple combination (IMI-DUR
1:1 in the presence of AMOX ﬁxed at 8 m g/mL) had the greatest activity, with an MIC
range of #0.06 to 2 m g/mL and an MIC50/MIC90 of #0.06/0.25 m g/mL (Table 1 and
Fig. 2).
Cefuroxime (CXM) alone had less activity than IMI, with an MIC50/MIC90 of 8/16 m g/
mL against this collection of isolates. Addition of AMOX at a ﬁxed concentration of
8 m g/mL to CXM improved the MIC50/MIC90 by one dilution (to 4/8 m g/mL). DUR added
to CXM in a ﬁxed 1:1 ratio had a greater effect, lowering the MIC50/MIC90 to 2/2 m g/mL.
The triple combination (CXM-DUR titrated 1:1 in the presence of 8 m g/mL AMOX) was
very potent and similar to the triple combination of IMI-DUR-AMOX, with an MIC range
of #0.06 to 1 m g/mL and an MIC50/MIC90 of #0.06/0.25 m g/mL (Table 1 and Fig. 2).
Kinetics of BlaMab inactivation by DUR is superior to AVI and REL. We next
sought to determine the biochemical parameters of Mab inactivation by DUR under
steady-state conditions using a reporter substrate, nitroceﬁn. We previously reported
apparent Ki (Ki app) values for the inhibition of BlaMab by avibactam (AVI) and relebactam
(REL) (0.30 6 0.03 m M and 136 6 14 m M, respectively) (9). For DUR, we determined a
Ki app (4.0  1023 6 0.8  1023 m M) nearly 75-fold lower than that of avibactam (Table 2).
The k2/K or “on rate” constant for DUR with BlaMab was 1.0  107 6 0.3  107 M21 s21,
nearly 30-fold and 17,000-fold higher than the values with avibactam and relebactam,
respectively. The koff and half-life (t1/2) with DUR were similar to those with avibactam and
January/February 2022 Volume 13 Issue 1 e03529-21
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are available only for imipenem and are as follows: susceptible (#8 m g/mL), intermediate (16 m g/mL), and resistant ($32 m g/mL).
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DUR had a slightly higher turnover number (kcat/kinact). We thus calculated the dissociation
constant (Kd) to be 0.2 6 0.1 nM, which again is comparatively lower than that of avibactam and relebactam, Taken together, these kinetic data show that DUR is a highly potent
inhibitor of BlaMab.
Timed electrospray ionization mass spectrometry. (i) Capturing DUR carbamoylenzyme complex formation with Mab BlaMab. In order to conﬁrm DUR inhibition of
BlaMab by covalent binding, we next aimed to capture carbamoyl-enzyme complexes
between DUR and BlaMab with timed electrospray ionization mass spectrometry. The
compound was incubated in excess with BlaMab for 2 h. Carbamoyl-enzyme complexes
of BlaMab with avibactam and relebactam were previously reported (9). As expected, a
peak corresponding to the mass of a BlaMab-DUR carbamoyl-enzyme complex was seen
(Fig. 3A).
(ii) DUR binds to LdtMab2, LdtMab3, LdtMab4, and D,D-c. On the basis of DUR intrinsic
antimicrobial activity, we explored whether there was formation of stable acyl-enzyme
complexes with DUR and several Ldts and the D,D-c of Mab. We previously captured
carbamoyl-enzyme complexes between avibactam and relebactam with these
enzymes (9). Again, excess DUR was incubated with enzyme for 2 h. DUR formed

TABLE 2 Kinetic parameters of BlaMab inhibition by DUR, relebactam, and avibactama
BlaMab
Durlobactam
Avibactam
Relebactam
aRelebactam

Ki app (mM)
(4.0 6 0.8)  1023
0.30 6 0.03
140 6 14

k2/K (M21s21)
(1.0 6 0.3)  107
(3.4 6 0.4)  105
(6.0 6 0.6)  102

Koff (s21)
(2.0 6 0.2)  1023
(2.0 6 0.2)  1023
(1.0 6 0.1)  1021

t1/2 (min)
6.0 6 0.6
6.0 6 0.6
12 6 1.2

Kd (nM)
0.2 6 0.1
6.0 6 0.6
(1.7 6 0.2)  103

Kcat/kinact
4
1
3

and avibactam values were previously determined (9). t1/2 = ln2/koff and Kd = koff/(k2/K).
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FIG 2 MIC distribution against 101 clinical isolates of Mycobacterium abscessus (Mab) subsp. abscessus. The drugs used were cefuroxime (CXM),
durlobactam (DUR), amoxicillin (AMOX), and imipenem (IMI). When more than two drugs were combined, AMOX was added at a ﬁxed concentration of
8 m g/mL to serial dilutions of CXM-DUR or IMI-DUR. Mab isolates were incubated with test agents at 30°C for 48 h, and MIC was deﬁned as lowest
antibiotic concentration that prevented visible bacterial growth.
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FIG 3 Timed mass spectrometry measuring durlobactam acyl-enzyme complex formation between Mab BlaMab (A),
D,D-c (B), and L,D-transpeptidases LdtMab2 (C), LdtMab3 (D), and LdtMab4 (E).

carbamoyl-enzyme complexes with D,D-c (Fig. 3B), LdtMab2, and LdtMab4 (Fig. 3C and E).
A complex was not captured with LdtMab3 (Fig. 3D and Table 3). These binding patterns
are reminiscent of those with avibactam and relebactam except that binding was not
observed between relebactam and LdtMab4.
(iii) AMOX binds to D,D-c but not to LdtMab2, LdtMab3, and LdtMab4. In order to further explore a biochemical rationale supporting the observation that the addition of
AMOX further lowered MICs when added to IMI-DUR and CXM-DUR, we sought to
investigate whether AMOX formed acyl-enzyme complexes with LdtMab2, LdtMab3,
LdtMab4, and D,D-c. In these investigations, AMOX was incubated in excess with enzymes
for 2 h. Consistent with previous studies examining the activity of penicillins and Mab
Ldts, acyl-enzyme complexes of AMOX with Ldts were not captured. In contrast, an
acyl-enzyme complex with AMOX and D,D-c was captured, demonstrating that it is a
potential target of the drug (Table 3).
Molecular modeling of DUR in the active site of BlaMab. To better describe the
potential molecular basis of DUR inhibition of BlaMab, we performed molecular modeling of
DUR in the active site of BlaMab. We previously described the positioning of avibactam and
relebactam in BlaMab using molecular modeling (9). Starting with the Michaelis-Menten
complex, we show that DUR is well positioned in the active site of the enzyme (Fig. 4A)
and forms potential hydrogen bonds with catalytic site residues N132, S130, and K232. The
DBO ring may be stabilized by W105 and by hydrophobic interactions between F237 with
the C-3 methyl group of DUR (Fig. 4B). While W105 and F237 had a favorable interaction
January/February 2022 Volume 13 Issue 1 e03529-21
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TABLE 3 Mass spectrometry analyses of BlaMab, LdtMab 2,3,4, and D,D-c alone and incubated
with durlobactam
Protein
(nominal MWa [Da])
BlaMab (28,432)

Compound
(nominal MW [Da])
None
Durlobactam (276)

Observed MW
(±5 Da)
28,432
28,709

1277

LdtMab2 (39,214)

None
Durlobactam (276)
Amoxicillin (365)

39,214
39,492
39, 214

1278
10

LdtMab3 (44,791)

None
Durlobactam (276)
Amoxicillin (365)

44,791
44,791
44,791

10
10

LdtMab4 (32,565)

None
Durlobactam (276)
Amoxicillin (365)

32,565
32,841
32,841

1276
10

Mab D,D-carboxypeptidase (26,789)

None
Durlobactam (276)
Amoxicillin (365)

26,789
27,066
27156

1277
1367

aMW,

Changes in MWb

molecular weight.
accuracy, 65 Da.

with DUR, in our previous molecular docking of BlaMab, we hypothesized these residues
were a source of steric hindrance for the piperidine ring of relebactam (9).
When the carbamoyl-enzyme complex between BlaMab and DUR is formed (Fig. 4C),
the carbamoyl group is positioned into the oxyanion hole, forming stabilizing hydrogen bond interactions with (S70:NH, G235:NH); there are also steric interactions
between the DBO ring and W105 and hydrogen bonds (H-bonds) with K232, S130,
N132, and K73. All these interactions support the ﬁnding that DUR is a potent and efﬁcient inhibitor of BlaMab.
Molecular modeling of DUR in the active site of D,D-c and LdtMab2. To assess the
potential interactions between D,D-c and DUR, the molecular docking of DUR into the
active site of D,D-c was performed and analyzed. The docking of intact DUR generated
the formation of Michaelis-Menten complex (Fig. 5A) with the carbamoyl group at C-7
perfectly positioned into the oxyanion hole, close to nucleophilic S70 and F230:NH.
When the carbamoyl-enzyme complex (Fig. 5B) between D,D-c and DUR is formed, the
carbamoyl is maintaining the position into the oxyanion hole (H-bond interactions
with S70:NH and F230:NH) and the sulfate group makes H-bonds with Q213 and S123.
Using the data from mass spectrometry, which show the formation of stable complex between DUR and LdtMab2 after 2 h incubation (Fig. 3C), and previous molecular
studies (9), the molecular docking of DUR was performed into the “open” active site of
LdtMab2. In Ldts, C351 is the catalytic residue (24). When intact DUR is docked into the
active site of LdtMab2 (see Fig. 8A), the carbamoyl is positioned into the proposed catalytic site with H-bond formation with C351:NH and G351:NH. Based on the molecular
dynamic (MD) simulation of LdtMab2 and DUR Michaelis-Menten complex (Fig. 6A), the
distance between C351:SH and the H333:ND2 imidazole ring is less than 2 Å. This
makes it possible for the activation (deprotonation) of the thiol group of C351 by H333
imidazole ring and provides assistance with the formation of the thio ester complex
(Fig. 6B). The ﬁrst step is deprotonation of a thiol (C351) in the enzyme’s active site by
H333 (which is part of the catalytic dyad, C351-H333); this is followed by nucleophilic
attack by the deprotonated cysteine's anionic sulfur on the carbonyl carbon (C-7)
(Fig. 7). When the thioester was formed, the results of the docking generated several
possible conformations (Fig. 6C, with carbamoyl “out” of oxianion hole, and Fig. 6D,
with carbamoyl toward oxianion hole). These results and the fact that the complex
January/February 2022 Volume 13 Issue 1 e03529-21
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between LdtMab2 and DUR was stable for more than 2 h (previous data with avibactam
show strong interaction for more than 8 h, and up to 4 weeks) (24) suggest that DUR
may form a long-lived complex in the active site of LdtMab2, without undergoing
deacylation.
Molecular modeling of AMOX in the active site of D,D-c. The formation of the acyl
complex of AMOX with D,D-c captured by the timed mass spectroscopy was examined

FIG 5 Molecular docking of DUR into the active site of D,D-c, and the formation of Michaelis-Menten (A) and
carbamoyl enzyme complexes (B) between D,D-carboxypeptidases and DUR. The carbamoyl is positioned into
the oxyanion hole (H-bond interactions with S70:NH and F230:NH), and the SO32 group makes H-bonds with
Q213 and S123.
January/February 2022 Volume 13 Issue 1 e03529-21
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FIG 4 Molecular docking of DUR into the active site of BlaMab as Michaelis-Menten complex. (A) DUR
is perfectly positioned into the active site of the enzyme and makes H-bond interactions with
catalytic residues N132, S130, and K232. (B) The DBO ring is stabilized by W105 and by hydrophobic
interactions of F237 with the methyl group of DUR. (C and D) The carbamoyl-enzyme complex
between BlaMab and DUR is formed (C), and productive interactions with the enzyme are created (D).
The carbamoyl is positioned into the oxyanion hole (H-bond interactions with S70:NH and G235:NH),
the steric interactions between DBO and W105 are preserved, and H-bonds with K234, S130, N132
and K73 are formed.

®

FIG 6 Intact durlobactam (DUR) was docked into the open active site of LdtMab2 (A). The molecular dynamics of the
Michelis-Menten complex suggest that His333 activates (deprotonates) the thiol group of Cys351 and assists the acyltransfer step. The nucleophilic Cys351 attacks C6 of DUR and forms the acyl-enzyme complex.

using molecular docking. Flexible docking does not result in productive conformations
for acylation and covalent bond formation (ﬁgure not shown). Manual docking, followed by minimization and bond formation for acyl-enzyme complex, resulted in conformations with the AMOX carboxyl group positioned in the oxionion hole (S70:NH
and F230:NH), for Michaelis-Menten (Fig. 8A) and acyl-enzyme (Fig. 8B) complexes. In
both complexes, amoxicillin is making H-bond networks with active site cavity residues
(S70, F230, K73, and K227).
DISCUSSION
DUR enhances susceptibility of Mab to IMI, CXM, and AMOX. The ability of dual
b -lactam combinations (carbapenems and cephalosporin) to inactivate multiple Ddt
and Ldt targets, the relative stability of carbapenems against hydrolysis by BlaMab, and
the use of novel b -lactamase inhibitors all together support the notion that dual b -lactam therapy may be a potential candidate for evaluation against Mab. Combining two
b -lactams in several in vitro studies revealed promising results (9, 13, 25, 26). Here, the
results observed in our cell-based assays for dual b -lactam combinations present a
more complex picture. First, DUR had signiﬁcant intrinsic antimicrobial activity on its
own, which is supported by its ability to form stable complexes with the cell wall synthesis proteins LdtMab2, LdtMab4, and Mab D,D-c. Second, while DUR had a profound
effect on the MIC of AMOX, only a modest impact on the activity of IMI or CXM was
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observed. Third, the combination of AMOX with IMI or CXM revealed only modest
improvement. Last, the addition of DUR to the combination of AMOX with either IMI or
CXM resulted in profound reductions in MICs into submicromolar range (Table 4). This
hitherto unappreciated synergy seen by inhibition of D,D-c was very revealing.
In this context, we advance the idea that DUR leads to effective protection of AMOX,
allowing for synergy with IMI or CXM, respectively. A recent in vitro report noted that the
addition of AMOX at a ﬁxed concentration of 32 m g/mL lowered MICs when combined
with IMI and relebactam against Mab. The lower concentration of 8 m g/mL used in our
study proved to be effective and is attainable in patients using 500-mg three times daily
dose regimens (15). In vitro data for the activity of new DBOs and prior clinically approved
BLIs were previously reported (15, 17, 27). None of these drugs inhibited BlaMab as potently
as DUR and MIC values were at least fourfold higher. Further in vitro studies are needed,
but durlobactam in combination with b -lactam partners holds potential as an addition to
the relatively limited array of drugs available for Mab infections.
DUR is a potent and efﬁcient inhibitor of BlaMab. As a b -lactamase with a broad
substrate proﬁle and relative resistance to previous BLIs, BlaMab remains a challenge to
be surmounted for the use of b -lactams in the treatment of Mab infections (6). The
DBOs avibactam and relebactam exhibit potent inhibitory activity against BlaMab and
restore susceptibility to AMOX (15, 21) and ceftaroline (9, 13). Relebactam combined

FIG 8 D,D-Carboxypeptidase and amoxicillin Michaelis-Menten (A) and acyl enzyme (B) complexes.
(Flexible docking does not result in productive conformations for acylation and covalent bond
formation [ﬁgure not shown]). Manual docking, followed by minimization and bond formation for
acyl enzyme complex, resulted in conformations with the amoxicillin carboxyl group positioned in
the oxyanion hole, and the formation of H-bond networking with active site cavity residues.
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FIG 7 His333 activates (deprotonates) the thiol group of C351 and assists the acyl-transfer step (22,
31). The nucleophilic C351 attacks C-6 of DUR and forms the acyl-enzyme complex. As for the
mechanism, the ﬁrst step is deprotonation of a thiol (C351) in the enzyme's active site by a histidine
(H333, not H349) residue. The next step is nucleophilic attack by the deprotonated cysteine’s anionic
sulfur on the peptide carbonyl carbon (C-6).
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Antibiotic(s)
DUR
Amoxicillin
AMOX-DUR
IMI
IMI-AMOX
IMI-DUR
IMI-DUR-AMOX
CXM
CXM-AMOX
CXM-DUR
CXM-DUR-AMOX

No. (cumulative %) of isolates inhibited at the following MIC (mg/mL):

TABLE 4 Cumulative MIC distribution of CXM, DUR, AMOX, and IMI for clinical isolates of Mab and ATCC 19977 control straina
MIC90
(mg/mL)
8
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with IMI-cilastatin and AMOX showed minimal enhancement of IMI bactericidal activity
against Mab isolates with declines in MIC ranges (15). We anticipated DUR would also
be an effective inhibitor of BlaMab. Our kinetics establish DUR as an effective inhibitor
to BlaMab and also demonstrate that it is more potent and efﬁcient than avibactam
with Ki app 75-fold lower and k2/K 30-fold higher.
Molecular modeling reveals unique interactions with the C-3 methyl group of
DUR and the hydrophobic W105 residue of BlaMab. While other class A b -lactamases
have a polar tyrosine at position 105 (Y105), BlaMab has a hydrophobic tryptophan
(W105). BlaMab also has a phenylalanine at position 237, which is usually occupied by alanine or serine in other class A b -lactamases. We had previously shown that these residues were a steric hindrance for the piperidine side group of relebactam into the active
site of BlaMab (9). In contrast, whereas W105 and F237 were obstacles for the interaction
of relebactam into the active site, they were favorable for DUR binding. In particular,
the C-3 methyl group of DUR has hydrophobic interactions with these residues in the
Michaelis-Menten complex. There is also a stabilizing interaction between the DUR
DBO ring and W105. These unique, favorable interactions likely underlie the enhanced
efﬁcacy of DUR as a BlaMab inhibitor compared to relebactam.
Blockage of LdtMab2 by IMI and DUR may prevent Ldts from catalyzing
transpeptidation. Penicillins and cephalosporins tend to be poor Ldt inhibitors, while
carbapenems and penems are typically the most potent (8). LdtMab2 is an ortholog of
LdtMt2 with signiﬁcant sequence homology (25). Mutant M. tuberculosis strains that are
deﬁcient in LdtMt2 were more susceptible to AMOX and clavulanic acid compared to
the wild type, and colonies were smaller and smooth (28). We hypothesize that inhibition of the LdtMab2 by IMI and DUR interferes with peptidoglycan transpeptidation and
sensitizes Mab to AMOX. In addition, disruption of peptidoglycan metabolism may
potentially alter bacterial b -lactamase production (21, 29). For AMOX to exhibit activity
against Mab, it must have a critical target to inhibit and must be protected against hydrolysis by BlaMab. We showed that AMOX formed stable acyl-enzyme complexes with
D,D-c and demonstrated potent inhibition of BlaMab activity by DUR. Figure 9 summarizes the interactions between AMOX, IMI, and DUR with Ldt2,4, D,D-c, and BlaMab.
Conclusions. In this study, we have demonstrated that DUR, a novel DBO BLI, is an
active agent with potent intrinsic activity against BlaMab, LdtMab2,4, and D,D-c with MIC
ranges comparable to those for IMI. The triple combination of DUR with AMOX and either IMI or CXM is highly potent. We hypothesize that DUR improves the b -lactam’s
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FIG 9 Interactions between Mab BlaMab, D,D-c, and L,D-transpeptidases LdtMab2 and LdtMab4 with IMI,
AMOX, and DUR. DUR is a potent inhibitor of BlaMab, provides protection of AMOX and IMI against
hydrolysis. Like IMI, DUR has intrinsic activity forming stable acyl enzyme complexes with LdtMab2 and
LdtMab4. AMOX has no activity against LdtMab2 and LdtMab4 but stably binds to D,D-c. The ability of DUR
to protect amoxicillin and imipenem against BlaMab and its intrinsic activity along with the dual
b -lactam target redundancy can explain the rationale behind potent activity of this combination.
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activity by protecting AMOX against the hydrolytic activity of BlaMab and by targeting
multiple steps in peptidoglycans synthesis. Data on use of dual b -lactams and BLI for
treatment of Mab are emerging and DUR may have potential as an active agent against
Mab, adding to the growing evidence of the potential clinical beneﬁt of utilizing dual
b -lactams with a BLI against serious Mab infections. The use of highly active b -lactam/
b -lactamase inhibitor combinations may prove to be effective therapy, reduce toxicity
in Mab treatment regimens, and lead to improved treatment outcomes by overcoming
resistance. Further studies are required to deﬁne the role of dual novel b -lactams and
BLI in the treatment of Mab infections.

Clinical strains, chemical reagents, and antibiotics. One hundred clinical respiratory isolates were
received at University Hospitals Cleveland Medical Center and MetroHealth Hospital in 2018 and from
the National Jewish Hospital, Denver, CO. Control M. abscessus type strain, ATCC 19977, was obtained
from the American Type Culture Collection (ATCC). Durlobactam (DUR) was a gift from Entasis
Therapeutics. Cefuroxime (CXM) salts (active ingredient), imipenem (IMI), and amoxicillin (AMOX) were
purchased from AchemBlock.
In vitro susceptibility testing. The MICs of CXM, IMI, and AMOX with or without DUR were determined using a serial microdilution method. Approximately 5  105 CFU/mL were inoculated into
Middlebrook 7H9 broth supplemented with 10% (vol/vol) oleic albumin dextrose catalase and 0.05%
(vol/vol) Tween 80. When more than two drugs were combined, AMOX was added at a ﬁxed concentration of 8 m g/mL to serial dilutions of CXM-DUR or IMI-DUR. Mab isolates were incubated with test agents
at 30°C for 48 h, and MIC was deﬁned as the lowest antibiotic concentration that prevented visible bacterial growth.
Cloning and puriﬁcation of BlaMab. A truncated sequence of Mab blaMab (D1–30 blaMab) was generated by Celtek Biosciences (Franklin, TN), cloned into the pET28(a)1 vector, and transformed into
Escherichia coli BL21(DE3). Cells were grown to an optical density at 600 nm (OD600) of 0.8, and protein
expression was induced with 1 mM isopropyl-D-1-thiogalactopyranoside (IPTG). After incubation for 18 h
at 16°C, cells were harvested and lysed using a QIA express nickel-nitrilotriacetic acid (Ni-NTA) fast-start
kit, followed by nickel column puriﬁcation of the His-tagged protein according to the manufacturer’s
protocol (Qiagen, Inc., Valencia, CA). Brieﬂy, the His tag was removed from the protein by adding thrombin (Novagen, Madison, WI) overnight at 4°C (1.6 U/mg protein). The cleaved protein was separated
from the His-tagged peptides by size exclusion chromatography using a HiLoad 16/60 Superdex 75 column (GE Healthcare Life Science, Uppsala, Sweden). The predicted mass of the BlaMab enzyme (28,433 Da)
was conﬁrmed by mass spectrometry.
Cloning and puriﬁcation of LdtMab2,3,4 and D,D-c. Cloning and puriﬁcation of LdtMab2,3,4 and D,D-c
were previously described (9, 25). Brieﬂy, truncated sequences of LdtMab 2,3,4 and D,D-c (D1–41) were generated by Celtek Biosciences and cloned into the pET28(a)1 vector with a TEV (tobacco etch virus) protease cleavage site prior to the start codon of the target protein sequences. Clones were transformed into
E. coli BL2(DE3) and grown at an OD600 of 0.8, and protein expression was induced with 0.25 mM IPTG.
After incubation for 18 h at 18°C, cells were harvested and stored at 220°C overnight. LdtMab2,3,4 and D,Dc cell pellets were resuspended in buffer containing 50 mM Tris (pH 8.0), 400 mM sodium chloride, and
1 mM Tris (2-carboxyethyl) phosphine hydrochloride (TCEP), followed by sonication and centrifugation.
The supernatant was passed through a His Prep FF 16/10 column (GE Healthcare) and washed with 25
column volumes of buffer, and bound protein was eluted with a gradient of 1 to 500 mM imidazole.
Eluted protein was subjected to dialysis overnight at 4°C in buffer containing 50 mM Tris (pH 8.0),
150 mM sodium chloride, and 0.5 mM TCEP in the presence of His-tagged TEV protease (ratio of TEV protease to LdtMab2,3,4 and D,D-c, 1:30). To remove the His tag, uncleaved fusion protein, and His-tagged TEV
protease, passage over the His Prep FF 16/10 column was performed. Fractions containing LdtMab2,3,4 and
D,D-c were pooled, concentrated, and stored in 20% glycerol at 220°C.
Mass spectrometry analyses. Ten micrograms of BlaMab, LdtMab2,3,4, and Mab D,D-c was incubated at
room temperature with substrate (DUR) at a molar ratio of 1:20 for 2 h in 50 mM Tris-HCl (pH 7.5) and
300 mM sodium chloride for a total reaction volume of 20 m l. Reactions were quenched with 10 m l acetonitrile, and the mixtures were added to 1 ml of 0.1% formic acid in water. Samples were analyzed
using a quadrupole time-of-ﬂight (Q-TOF) Waters Synapt-G2-Si electrospray ionization mass spectrometer (ESI-MS) and Waters Acquity H class ultraperformance liquid chromatography (UPLC) with a BEH C18
1.7-m m column (2.1 by 50 mm). The Synapt G2-Si spectrometer was calibrated with sodium iodide with
an m/z mass range of 50 to 2,000. MassLynx V4.1 was used to deconvolute protein peaks. The tune settings for each sample were as follows: capillary voltage at 3 kV, sampling cone at 35 V, source offset at
35, source temperature of 100°C, desolvation temperature of 500°C, cone gas at 100 L/h, desolvation gas
at 800 L/h, and 6.0 nebulizer. Mobile phase A was 0.1% formic acid (FA) in water. Mobile phase B was
0.1% FA in acetonitrile. The mass accuracy for this system is 65 Da.
Inactivation kinetics. The kinetic parameters of BlaMab with avibactam and relebactam were previously determined (9). DUR inhibition kinetics were performed with puriﬁed BlaMab enzyme as previously
described (9, 30). In brief, the reaction scheme is represented in equation 1:
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E1I

k1
k21

E:I

k2
k22

E2I

(1)

where E is the enzyme and I is the inhibitor. Kinetic parameters were determined using an Agilent 8453
diode array spectrophotometer (Agilent Technologies, Inc., Santa Clara, CA), and reactions were conducted in 100 mM morpholino ethanesulfonic acid (MES) (pH 6.4) at 20°C. A direct competition assay
was performed to approximate the relative Michaelis constant (Ki app) of the inhibitor which was the inhibitor concentration leading to reduction of the velocity by 50% as measured by nitroceﬁn hydrolysis.
A ﬁnal concentration of 5  Km of nitroceﬁn (NCF) (KmNCF = 22 m M) was used as the indicator substrate in the
presence of 7.0 nM BlaMab. Initial velocities were measured over the ﬁrst 10 s of the reaction in the presence
of durlobactam concentrations ranging from 0 to 0.05 m M. The Ki app was determined by dividing the y intercept over the slope of the simple linear regression of 1/velocity versus the concentration of DUR. This value
was then corrected to account for the afﬁnity of nitroceﬁn for BlaMab according to equation 2:
Ki app ¼

Ki app observed
1 1 ½NCF=Km NCF

(2)

To determine the acylation rate (k2/K), which is the second-order rate constant for enzyme and inhibitor complex inactivation with K = k1/k21, assays were performed using ﬁxed concentrations of enzyme
and NCF and increasing concentrations of DUR. The progress curves to obtain observed k (kobs) values
for inactivation were ﬁt graphically using equation 3:
y ¼ Vf x 1

ðV0 2 Vf Þð1 2 e2kobs x Þ
1 A0
kobs

(3)

where Vf is the ﬁnal velocity, V0 is the initial velocity, and A0 is the initial absorbance at 482 nm. Fitting to
equation 3 was performed in Origin 8.1 (Origin Lab, Northampton, MA). The values for kobs versus DUR
concentration were plotted. The acylation rate constant was determined by correcting the slope of the
line to account for the afﬁnity of nitroceﬁn (KmNCF) using equation 4:
(4)

The off-rate constant (koff) was determined by incubating BlaMab with DUR at 500  Kiapp for 5 min.
The mixture was diluted 1:1,000, and 100 m M nitroceﬁn was added. Progress curves of nitroceﬁn hydrolysis were measured and ﬁtted to single exponential decay equation to obtain koff. Reaction mixtures
containing BlaMab alone and DUR alone were used as controls. The residence half-life (t1/2) of the drugenzyme complex was (ln2/koff). Partition ratios (kcat/kinact) were obtained by incubating BlaMab with
increasing ratios of DUR for 24 h. The ratio of inhibitor to enzyme required to inhibit the hydrolysis of
nitroceﬁn by .90% is kcat/kinact.
Molecular modeling. The crystal structure of class A b -lactamase from M. abscessus (PDB accession
no. 4YFM) was used for simulation and molecular docking. Discovery Studio 2020 Client (BIOVIA,
Dassault Systémes, 2020, San Diego) molecular modeling software was used as previously described (9).
The structure was minimized using a conjugate gradient method, with a root mean square (RMS) gradient of 0.001 kcal/(mol  Å). Generalized Born with a simple Switching (GBSW) solvation model was
used, and long-range electrostatics were treated using a Particle Mesh Ewald method with periodic
boundary condition. The SHAKE algorithm was applied.
The intact and acyl DUR was built and minimized. The CDOCKER protocol was used to dock the DUR
into the active site of BlaMab. Similarly, D,D carboxypeptidases crystal structure (PDB accession no. 4RYE)
and LdtMab2 (PDB accession no. 5UWV) were used for docking DUR into the active site. The protocol uses
a CHARMm-based molecular dynamics (MD) scheme to dock ligands into a receptor binding site.
Random ligand conformations were generated using high-temperature MD. The conformations are then
translated into the binding site. Candidate poses are created using random rigid-body rotations, followed by simulated annealing. A ﬁnal minimization is used to reﬁne the ligand poses. The generated
poses were analyzed, and the best ranked poses were used to create the Michaelis-Menten and acylenzyme complexes and were further minimized.
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